UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184
UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.
Stocks · News reference
Protagonist Therapeutics Announces Participation in Four Investment Bank Conferences in November 2026
Protagonist Therapeutics announced that its senior management team will participate in four upcoming investment bank conferences throughout November 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190
Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.
Protagonist Therapeutics Announces $300M Buyback Plan